TG Therapeutics Inc (TGTX)
Solvency ratios
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.42 | 0.26 | 0.27 | 0.30 | 0.30 | 0.44 | 0.49 | 0.37 | 0.33 | 0.27 | 0.22 | 0.18 | 0.00 | 0.00 | 0.00 | 0.01 | 0.06 | 0.08 | 0.29 | 0.18 |
| Debt-to-capital ratio | 0.56 | 0.37 | 0.39 | 0.38 | 0.38 | 0.71 | 0.78 | 0.55 | 0.41 | 0.35 | 0.28 | 0.22 | 0.00 | 0.00 | 0.00 | 0.01 | 0.08 | 0.10 | 1.05 | 0.43 |
| Debt-to-equity ratio | 1.27 | 0.58 | 0.63 | 0.62 | 0.60 | 2.42 | 3.52 | 1.21 | 0.71 | 0.53 | 0.39 | 0.28 | 0.00 | 0.00 | 0.00 | 0.01 | 0.09 | 0.11 | — | 0.75 |
| Financial leverage ratio | 3.05 | 2.26 | 2.33 | 2.05 | 2.01 | 5.46 | 7.19 | 3.30 | 2.17 | 1.95 | 1.78 | 1.60 | 1.32 | 1.26 | 1.23 | 1.20 | 1.60 | 1.52 | — | 4.22 |
TG Therapeutics Inc's solvency ratios show mixed trends over the periods analyzed. The debt-to-assets ratio has varied, indicating the company's ability to cover its obligations with its assets has fluctuated. The debt-to-capital ratio also demonstrates variability, reflecting the proportion of debt in the company's capital structure. The debt-to-equity ratio, while fluctuating, showed higher levels of debt relative to equity in some periods, suggesting higher financial risk. The financial leverage ratio has been inconsistent, indicating changes in the company's financial structure and potential risk exposure. Overall, TG Therapeutics Inc's solvency position appears to have experienced fluctuations, warranting continued monitoring to assess its financial health and risk management strategies.
Coverage ratios
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | 0.09 | 13.84 | 4.08 | 1.64 | -1.45 | -15.36 | -15.71 | -18.92 | -27.80 | -36.41 | -50.35 | -61.15 | -57.88 | -52.82 | -44.48 | -43.22 | -32.40 | -29.12 | -32.31 | -31.98 |
The interest coverage ratio for TG Therapeutics Inc has shown significant fluctuations over the periods under review. The interest coverage ratio indicates the company's ability to cover its interest expenses with its operating income. A ratio below 1.0 suggests that the company is not generating enough operating income to cover its interest expenses.
In recent quarters, the company has struggled to cover its interest payments, as evidenced by negative ratios in some periods. This is concerning as it indicates that the company's operating income may not be sufficient to meet its interest obligations, potentially leading to financial distress.
Moreover, the significant variance in the interest coverage ratio suggests inconsistent profitability and financial performance. The ratio has ranged from -61.15 to 13.84 over the periods, indicating instability in the company's ability to service its debt through its operating earnings.
Investors and creditors closely monitor the interest coverage ratio as it reflects the company's financial health and ability to meet its debt obligations. A sustained low or negative interest coverage ratio could raise concerns about the company's solvency and ability to manage its debt effectively. Management should focus on improving operational efficiency and profitability to strengthen the company's ability to cover its interest expenses in the future.